Drug Trial Radar · NCT06610526
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
731
Actual
Start
Aug 23, 2024
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
Conditions
- Chronic Kidney Disease
Interventions
DapagliflozinDrug
Dapagliflozin by oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death.Time frame: Up to a median follow-up time of 24 months
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Dongguan, China
Research Site
Foshan, China
Research Site
Fuyang, China
Research Site
Fuzhou, China
Research Site
Ganzhou, China
Research Site
Harbin, China
Research Site
Hefei, China
Research Site
Hengyang, China
Research Site
Huaian, China
Research Site
Huizhou, China
Research Site
Jilin City, China
Research Site
Jinan, China
Research Site
Jining, China
Research Site
Lanzhou, China
Research Site
Linyi, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanning, China
Research Site
Ningbo, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Suzhou, China
Research Site
Taian, China
Research Site
Tianjin, China
Research Site
Wuhu, China
Research Site
Wuxi, China
Research Site
Xi'an, China
Research Site
Xiamen, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.